Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2020-12-18 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science dated December 18, 2020, communicating the results from a Phase 2B/3 study evaluating masitinib in Alzheimer's disease. It details clinical trial results (ADAS-Cog, ADCS-ADL scores), mechanism of action, and includes quotes from Key Opinion Leaders (KOLs) and background information on the drug and company. This format—a detailed announcement of clinical trial outcomes and scientific data—is characteristic of an Earnings Release (ER) or a specific scientific/clinical update. Since it is a comprehensive communication of study results, it is more substantial than a simple 'Earnings Release' (ER) which usually focuses on financial metrics. It is not a full Annual Report (10-K), an Interim Report (IR), or a standard Investor Presentation (IP). Given the focus on communicating study results and scientific findings, it aligns best with a detailed announcement, but none of the codes perfectly capture a 'Clinical Trial Result Announcement'. However, based on the provided definitions, it is a communication of results that is not a formal financial report (10-K, IR) or a presentation deck (IP). It is a press release announcing scientific data. If this were a formal filing, it might be an 8-K itemizing results, but as a press release, it functions as a major corporate update. Since it details clinical trial results and scientific findings, it is closest to an Investor Presentation (IP) in content depth, but the format is a press release. Given the options, and recognizing that many clinical updates are disseminated via press release, we must choose the best fit. It is not a standard ER (financials), nor a CT (transcript). It is a detailed scientific update. If we consider the content as an 'Investor Presentation' in substance, that might fit, but the format is a press release. The document explicitly states the presentation is available elsewhere, suggesting this text is the accompanying announcement. This strongly suggests it is a Report Publication Announcement (RPA) or a Regulatory Filing (RNS) if it were purely administrative. Since it contains substantial scientific data, it is often classified as an Investor Presentation (IP) when the content is rich, or sometimes an Earnings Release (ER) if it's tied to a reporting period, though here it is a specific drug update. Given the depth of the scientific data and the mention of a linked presentation, 'Investor Presentation' (IP) is a strong candidate for the *content type*, even if the delivery mechanism is a press release. However, if we strictly follow the 'Menu vs Meal' rule, this is the announcement *about* the presentation/results. Since it is a detailed communication of results, and not just a notice that a report is attached, it is more than an RPA. Let's re-evaluate: It is a press release announcing study results. This type of announcement often falls under 'Regulatory Filings' (RNS) if it's a required disclosure, or sometimes is grouped with ERs. Since it is a major corporate event (clinical trial results), and not a standard financial report, RNS is the safest fallback for a non-standard announcement. However, the content is highly specific to investment information (drug development). Given the options, and the fact that it is a detailed communication of results, I will classify it as an Investor Presentation (IP) based on the substance of the information provided, as it functions as a detailed update for investors on R&D progress, even though it's in press release format.
2020-12-18 English
AB Science communique les résultats de l’étude de phase 2B/3 évaluant le masitinib dans la maladie d’Alzheimer
Investor Presentation Classification · 1% confidence The document is a press release dated December 18, 2020, announcing the results of a Phase 2B/3 study (AB09004) for Masitinib in Alzheimer's disease. It details clinical trial outcomes (ADAS-Cog, ADCS-ADL scores), mechanism of action, and includes quotes from key opinion leaders (KOLs) and biographies of the speakers. This format—a detailed announcement of clinical trial results and associated data presentation—is characteristic of an Earnings Release (ER) or a specific type of Investor Presentation (IP) if it were a slide deck. However, since it is a formal press release detailing significant clinical data and study outcomes, it functions primarily as an announcement of financial/development progress. Given the options, it is a detailed announcement of results, which often overlaps with an Investor Presentation (IP) if it summarizes data intended for investors, or an Earnings Release (ER) if it's the primary way results are disseminated. Since it explicitly mentions that the presentation of these results is available via a link, and the text itself is a detailed summary of clinical trial data, it strongly aligns with an Investor Presentation (IP) which often accompanies or summarizes such data releases, or an Earnings Release (ER) if it's the primary results announcement. Because it focuses heavily on clinical trial data and mechanism of action, 'Investor Presentation' (IP) is a strong fit, as it presents data in a structured, persuasive manner for investors, even if delivered via a press release format. However, the core function here is the *release* of the results, which is often categorized as an ER if it's the first formal disclosure of period results, or IP if it's a dedicated presentation deck. Given the depth of the clinical data summary, IP is slightly more specific than a typical high-level ER. If this were a quarterly report, it would be classified as IR. Since it's a specific study result announcement, IP is the best fit among the choices for detailed data dissemination to investors, although RPA could also apply if it were just announcing the availability of the presentation. Since the text contains the core results, IP is chosen over RPA.
2020-12-18 French
AB Science - Résultats de l'Assemblée Générale Extraordinaire du 16 décembre 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled "RESULTATS DE L'ASSEMBLEE GENERALE EXTRAORDINAIRE DU 16 DECEMBRE 2020" (Results of the Extraordinary General Meeting of December 16, 2020). It details the resolutions voted upon, the approval status, and the voting results (number of favorable/unfavorable votes). This content directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Although it relates to an AGM/EGM, the focus is on the *results* of the vote, not the presentation materials (AGM-R) or the proxy solicitation (PSI).
2020-12-17 French
AB Science publie un communiqué de presse correctif concernant les informations sur les effets indésirables de l'étude AB09004 annoncées le 16 décembre 2020
Earnings Release Classification · 1% confidence The document is titled "AB SCIENCE PUBLIE UN COMMUNIQUE DE PRESSE CORRECTIF" (AB Science Publishes a Corrective Press Release). It details a correction to previously released information regarding adverse events in a clinical study (AB09004 for Alzheimer's disease treatment). This is a specific announcement correcting prior data, not a full periodic report (like 10-K or IR) or a general regulatory filing (RNS). Since it is an announcement correcting specific operational/clinical data, it fits best under the general category of Regulatory Filings (RNS) as a specific press release correction, or potentially a Legal/Regulatory update if the error was significant, but RNS serves as the best general catch-all for non-standard, specific corporate announcements that aren't earnings, dividends, or management changes. Given the nature of correcting a press release, RNS is the most appropriate classification among the provided options, as it is a specific, non-standard corporate communication. FY 2020
2020-12-17 French
AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
Regulatory Filings Classification · 1% confidence The document is explicitly titled a 'CORRECTIVE PRESS RELEASE' issued by AB Science. It corrects specific adverse event data from a previous announcement regarding a clinical study (AB09004). This format—a brief announcement correcting or providing key updates outside of a full periodic report (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing specific, time-sensitive operational/data information (even if corrective), it aligns best with the 'Earnings Release' category, which often encompasses initial results announcements and subsequent corrections, or the general 'Regulatory Filings' category. Given the content is a correction to study results, which often accompanies or follows an earnings announcement, ER is a strong candidate. However, since it is a correction to a press release and not the primary earnings report itself, and it doesn't contain the full quarterly financial summary, classifying it as a general Regulatory Filing (RNS) is the safest and most accurate fallback for non-standard, time-sensitive corporate announcements that aren't explicitly defined elsewhere (like DIRS, DIV, or MANG). The length (5100 chars) is substantial enough to be more than just a placeholder notice (RPA). I will classify it as RNS as it is a general regulatory announcement correcting prior information.
2020-12-17 English
AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease
Investor Presentation Classification · 1% confidence The document is a press release dated December 16, 2020, announcing that AB Science will host a live webcast on December 17, 2020, to discuss recently reported Phase 2B/3 masitinib trial results in Alzheimer's Disease. It details the speakers (KOLs), the agenda, and dial-in information. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing announcing the results themselves (which would likely be an ER or RNS). Instead, it is an announcement specifically about an upcoming investor/analyst event (a webcast) where results and strategy will be discussed in detail, featuring presentations and a Q&A. This aligns best with an Investor Presentation (IP) or a general announcement about an event where investors are being briefed. Since it is an announcement of a presentation/discussion event, Investor Presentation (IP) is the most fitting category, as it details what will be presented to investors, even though the presentation itself is scheduled for the next day.
2020-12-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.